Therapeutic strategy for the treatment with hypertensive renal injury

Koichi Hayashi

Research output: Contribution to journalArticle

Abstract

Hypertension constitutes a pivotal determinant of the progression of renal disease, which would raise the risk for cardiovascular events. From the standpoint of renal micro-circulation, correction of glomerular hypertension could retard the development of renal injury, which is attainable by the reduction in renal efferent arteriolar resistance as well as systemic blood pressure. Although both ACE inhibitors and angiotensin receptor blockers are established as a tool for improving glomerular hypertension, whether calcium antagonists ameliorate this abnormality remains unclear. However, recent clinical trials including ALLHAT and INSIGHT demonstrate a beneficial action of amlodipine and nifedipine on the development of renal injury. Therefore, calcium antagonists can be used not only as a first line drug, but also as add-on therapy that could potentiate the hypotensive action of underlying medication.

Original languageEnglish
Pages (from-to)135-141
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Volume62
Issue number1
Publication statusPublished - 2004

Fingerprint

Kidney
Wounds and Injuries
Hypertension
Calcium
Amlodipine
Renal Circulation
Angiotensin Receptor Antagonists
Therapeutics
Nifedipine
Angiotensin-Converting Enzyme Inhibitors
Disease Progression
Clinical Trials
Blood Pressure
Pharmaceutical Preparations

Cite this

Therapeutic strategy for the treatment with hypertensive renal injury. / Hayashi, Koichi.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 62, No. 1, 2004, p. 135-141.

Research output: Contribution to journalArticle

@article{8c51e2c675d348dc85c1dda3bb075bbe,
title = "Therapeutic strategy for the treatment with hypertensive renal injury",
abstract = "Hypertension constitutes a pivotal determinant of the progression of renal disease, which would raise the risk for cardiovascular events. From the standpoint of renal micro-circulation, correction of glomerular hypertension could retard the development of renal injury, which is attainable by the reduction in renal efferent arteriolar resistance as well as systemic blood pressure. Although both ACE inhibitors and angiotensin receptor blockers are established as a tool for improving glomerular hypertension, whether calcium antagonists ameliorate this abnormality remains unclear. However, recent clinical trials including ALLHAT and INSIGHT demonstrate a beneficial action of amlodipine and nifedipine on the development of renal injury. Therefore, calcium antagonists can be used not only as a first line drug, but also as add-on therapy that could potentiate the hypotensive action of underlying medication.",
author = "Koichi Hayashi",
year = "2004",
language = "English",
volume = "62",
pages = "135--141",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "1",

}

TY - JOUR

T1 - Therapeutic strategy for the treatment with hypertensive renal injury

AU - Hayashi, Koichi

PY - 2004

Y1 - 2004

N2 - Hypertension constitutes a pivotal determinant of the progression of renal disease, which would raise the risk for cardiovascular events. From the standpoint of renal micro-circulation, correction of glomerular hypertension could retard the development of renal injury, which is attainable by the reduction in renal efferent arteriolar resistance as well as systemic blood pressure. Although both ACE inhibitors and angiotensin receptor blockers are established as a tool for improving glomerular hypertension, whether calcium antagonists ameliorate this abnormality remains unclear. However, recent clinical trials including ALLHAT and INSIGHT demonstrate a beneficial action of amlodipine and nifedipine on the development of renal injury. Therefore, calcium antagonists can be used not only as a first line drug, but also as add-on therapy that could potentiate the hypotensive action of underlying medication.

AB - Hypertension constitutes a pivotal determinant of the progression of renal disease, which would raise the risk for cardiovascular events. From the standpoint of renal micro-circulation, correction of glomerular hypertension could retard the development of renal injury, which is attainable by the reduction in renal efferent arteriolar resistance as well as systemic blood pressure. Although both ACE inhibitors and angiotensin receptor blockers are established as a tool for improving glomerular hypertension, whether calcium antagonists ameliorate this abnormality remains unclear. However, recent clinical trials including ALLHAT and INSIGHT demonstrate a beneficial action of amlodipine and nifedipine on the development of renal injury. Therefore, calcium antagonists can be used not only as a first line drug, but also as add-on therapy that could potentiate the hypotensive action of underlying medication.

UR - http://www.scopus.com/inward/record.url?scp=1642400595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642400595&partnerID=8YFLogxK

M3 - Article

C2 - 14737846

AN - SCOPUS:1642400595

VL - 62

SP - 135

EP - 141

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 1

ER -